Erratum to: Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis (Inflammatory Bowel Diseases(2022) 28 (S112) DOI: 10.1093/ibd/izac015.180)

Andrew Leber; Raquel Hontecillas; Nuria Tubau-Juni; Simon Lichtiger; Josep Bassaganya-Riera

doi:10.1093/ibd/izac055

Erratum to: Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis (Inflammatory Bowel Diseases(2022) 28 (S112) DOI: 10.1093/ibd/izac015.180)

Andrew Leber
, Raquel Hontecillas
, Nuria Tubau-Juni
, Simon Lichtiger
, Josep Bassaganya-Riera

Research output: Contribution to journal › Comment/debate

Abstract

Leber A, Hontecillas R, Tubau-Juni N, Lichtiger S, Bassaganya- Riera J. Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis. Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S112, https://doi.org/10.1093/ibd/izac015.180 The above abstract has been withdrawn by the authors.

Original language	English
Pages (from-to)	1938
Number of pages	1
Journal	Inflammatory Bowel Diseases
Volume	28
Issue number	12
DOIs	https://doi.org/10.1093/ibd/izac055
State	Published - 1 Dec 2022

Access to Document

10.1093/ibd/izac055

Fingerprint

Dive into the research topics of 'Erratum to: Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis (Inflammatory Bowel Diseases(2022) 28 (S112) DOI: 10.1093/ibd/izac015.180)'. Together they form a unique fingerprint.

Cite this

Leber, A., Hontecillas, R., Tubau-Juni, N., Lichtiger, S., & Bassaganya-Riera, J. (2022). Erratum to: Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis (Inflammatory Bowel Diseases(2022) 28 (S112) DOI: 10.1093/ibd/izac015.180). Inflammatory Bowel Diseases, 28(12), 1938. https://doi.org/10.1093/ibd/izac055

@article{b79ec6dc488f4e40ac397692748dde52,

title = "Erratum to: Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis (Inflammatory Bowel Diseases(2022) 28 (S112) DOI: 10.1093/ibd/izac015.180)",

abstract = "Leber A, Hontecillas R, Tubau-Juni N, Lichtiger S, Bassaganya- Riera J. Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis. Inflammatory Bowel Diseases, Volume 28, Issue Supplement\_1, February 2022, Page S112, https://doi.org/10.1093/ibd/izac015.180 The above abstract has been withdrawn by the authors.",

author = "Andrew Leber and Raquel Hontecillas and Nuria Tubau-Juni and Simon Lichtiger and Josep Bassaganya-Riera",

year = "2022",

month = dec,

day = "1",

doi = "10.1093/ibd/izac055",

language = "English",

volume = "28",

pages = "1938",

journal = "Inflammatory Bowel Diseases",

issn = "1078-0998",

publisher = "Oxford University Press",

number = "12",

}

Leber, A, Hontecillas, R, Tubau-Juni, N, Lichtiger, S & Bassaganya-Riera, J 2022, 'Erratum to: Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis (Inflammatory Bowel Diseases(2022) 28 (S112) DOI: 10.1093/ibd/izac015.180)', Inflammatory Bowel Diseases, vol. 28, no. 12, pp. 1938. https://doi.org/10.1093/ibd/izac055

Erratum to: Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis (Inflammatory Bowel Diseases(2022) 28 (S112) DOI: 10.1093/ibd/izac015.180). / Leber, Andrew; Hontecillas, Raquel; Tubau-Juni, Nuria et al.
In: Inflammatory Bowel Diseases, Vol. 28, No. 12, 01.12.2022, p. 1938.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum to

T2 - Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis (Inflammatory Bowel Diseases(2022) 28 (S112) DOI: 10.1093/ibd/izac015.180)

AU - Leber, Andrew

AU - Hontecillas, Raquel

AU - Tubau-Juni, Nuria

AU - Lichtiger, Simon

AU - Bassaganya-Riera, Josep

PY - 2022/12/1

Y1 - 2022/12/1

N2 - Leber A, Hontecillas R, Tubau-Juni N, Lichtiger S, Bassaganya- Riera J. Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis. Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S112, https://doi.org/10.1093/ibd/izac015.180 The above abstract has been withdrawn by the authors.

AB - Leber A, Hontecillas R, Tubau-Juni N, Lichtiger S, Bassaganya- Riera J. Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis. Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S112, https://doi.org/10.1093/ibd/izac015.180 The above abstract has been withdrawn by the authors.

UR - https://www.scopus.com/pages/publications/85143180351

U2 - 10.1093/ibd/izac055

DO - 10.1093/ibd/izac055

M3 - Comment/debate

C2 - 35489068

AN - SCOPUS:85143180351

SN - 1078-0998

VL - 28

SP - 1938

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

IS - 12

ER -

Leber A, Hontecillas R, Tubau-Juni N, Lichtiger S, Bassaganya-Riera J. Erratum to: Efficacy, Safety, and Tolerability of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis (Inflammatory Bowel Diseases(2022) 28 (S112) DOI: 10.1093/ibd/izac015.180). Inflammatory Bowel Diseases. 2022 Dec 1;28(12):1938. doi: 10.1093/ibd/izac055